

## **DxTernity Collaborates with City of Hope Medical Center on the Development of a Cancer Genomic Blood Test to Predict Response to Radiation Therapy**

DxTernity announced today that it is collaborating with the City of Hope Medical Center on the clinical development of a blood test that could possibly predict whether cancer patients about to undergo radiation therapy are likely to benefit from the treatment, as well as identify those who are at risk for radiation toxicity. This research program is being funded in part by the National Cancer Institute.

Radiation therapy or radiotherapy plays an important role in the fight against cancer with more than 60 percent of all patients receiving some form of radiation treatment. Despite its excellent overall safety profile, approximately 10 percent of patients experience radiation toxicity, while some patients may not benefit from the treatment. To address this clinical need, DxTernity is developing a genomic blood test to identify which patients are most likely to benefit from radiation treatment thereby allowing oncologists to minimize radiation exposure for unresponsive and sensitive patients, or use adjunctive therapies, such as immunotherapy, to improve radiotherapy response.

“Not knowing who will respond to radiation therapy or if they will experience radiation toxicity are on-going barriers to personalizing cancer treatment.”, says Professor Yi-Jen Chen, MD, the Principal Investigator of the trial from Radiation Oncology, City of Hope Medical Center. “We are excited to partner with DxTernity in advancing cancer research to address this problem.”

DxTernity’s radiotherapy response study (RADIANT) is initially focused on patients receiving radiation treatment to their abdominal-pelvic region. In addition to work with City of Hope Medical Center, DxTernity is also enrolling nationally online at [www.radiantstudy.com](http://www.radiantstudy.com) for qualified patients with the following cancers: prostate, colorectal, anal, esophageal, cervical, ovarian, uterine, gall bladder, kidney, stomach, pancreatic and testicular cancer. Interested patients can participate from the convenience of their home by self-collecting a fingerstick blood sample using DxTernity’s DxCollect® From-Home mailer kit prior to beginning radiotherapy treatment. By minimizing the burden of participating in this study, DxTernity hopes to cost-effectively increase the number of patients who are able to participate while advancing the treatment of cancer patients.

For research use only. Not for diagnostic procedures.

### **About RADIANT Study:**

The researchers behind RADIANT are working to develop a blood test to help doctors make more informed decisions about cancer radiation treatment. Cancer patients about to undergo radiation treatment are being enrolled at the City of Hope Medical Center and online through an at-home study. For the at-home study, a fingerstick collector kit is used to collect a few drops of blood from the comfort of home. Scientists will analyze the genomic markers in the blood to understand the individual patient’s biological response to radiation treatment. For more information, please visit [www.radiantstudy.com](http://www.radiantstudy.com).

This program is being funded in part through a Phase II SIBR Contract from the National Cancer Institute, Contract #HHSN261201600051C.

### **About DxTernity:**

DxTernity is a patient-centric genomics company bringing the power of real-world genomics with From-Home RNA monitoring to improving the management of immune-mediated diseases. With patented and proprietary technologies that engage patients where they live, DxTernity is increasing clinical study efficiency while transforming the management of immune-mediated disease by providing a more complete picture of an individual’s health. DxTernity also provides services and technologies to partner organizations including running population-scale genomic studies. For more information, please visit [www.dxterity.com](http://www.dxterity.com)

### **About City of Hope:**

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with [community](#) clinics throughout Southern California. It is ranked as one of “America’s Best Hospitals” in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of [bone marrow transplantation](#), [diabetes](#) and [numerous breakthrough cancer](#)

[drugs](#) based on technology developed at the institution.

Media Contact:

June Fujimoto

[press@dxterity.com](mailto:press@dxterity.com)

310-537-7857

---

<https://swkhold.investorroom.com/2017-09-21-DxTerity-Collaborates-with-City-of-Hope-Medical-Center-on-the-Development-of-a-Cancer-Genomic-Blood-Test-to-Predict-Response-to-Radiation-Therapy>